Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
Status:
Recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority
study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study
conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia
will demonstrate the benefit of statins for reducing the primary composite of death,
dementia, and persistent disability and secondary composites including mild cognitive
impairment (MCI) and cardiovascular events.
Phase:
Phase 4
Details
Lead Sponsor:
Duke University
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) National Institute on Aging (NIA) Wake Forest University Health Sciences